Cognitive impairment predicts outcomes for ICU survivors
Jul 01, 2022
Cognitive impairment at hospital discharge was linked to the risk of new physical disability at the six-month follow-up.
Certain antihypertensive agents may aid cognition in elderly
Jun 21, 2021
Memory recall is better for up to three years with blood-brain barrier-crossing renin-angiotensin drugs versus nonpenetrant counterparts.
Caregivers more likely to have subjective cognitive decline
Nov 19, 2021
“Healthcare professionals can support their patients and their patients’ caregivers by recognizing SCD and its associated challenges in providing care and providing compensatory strategies...
Prevalence of dementia estimated at 10 percent in 2016
Oct 24, 2022
The risk for dementia reduced with each additional year of education; dementia prevalence was higher for Blacks.
Dietary flavonoids may lower odds of subjective cognitive decline
Jul 30, 2021
Associations were strongest for flavones, flavanones, anthocyanins; the dose-response curve was steepest for flavones, then anthocyanins.
Prevalence of subjective cognitive decline 9.6 percent in ages 45 and up
Mar 13, 2023
Only 47.3% of those with subjective cognitive decline reported that they had discussed issue with healthcare professional.
Incident MI tied to faster declines in cognitive function over time
Jun 05, 2023
Incident myocardial infarction is not associated with a decrease in global cognition, memory or executive function but is associated with faster declines in those measures over time.
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.